These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10863026)

  • 1. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.
    Kohnken R; Buerger K; Zinkowski R; Miller C; Kerkman D; DeBernardis J; Shen J; Möller HJ; Davies P; Hampel H
    Neurosci Lett; 2000 Jun; 287(3):187-90. PubMed ID: 10863026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.
    Hu YY; He SS; Wang X; Duan QH; Grundke-Iqbal I; Iqbal K; Wang J
    Am J Pathol; 2002 Apr; 160(4):1269-78. PubMed ID: 11943712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Human tau N-terminal domain-specific monoclonal antibodies: screening and application in blood detection].
    Yan Z; Zhang Y; Jiang J; Liu Z; Wang H; Zhang Y; He J; Hong T
    Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1571-1583. PubMed ID: 38783817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Time Tau Protein Detection by Sandwich-Based Piezoelectric Biosensing: Exploring Tubulin as a Mass Enhancer.
    Li D; Scarano S; Lisi S; Palladino P; Minunni M
    Sensors (Basel); 2018 Mar; 18(4):. PubMed ID: 29565824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected.
    Suárez-Calvet M; Karikari TK; Ashton NJ; Lantero Rodríguez J; Milà-Alomà M; Gispert JD; Salvadó G; Minguillon C; Fauria K; Shekari M; Grau-Rivera O; Arenaza-Urquijo EM; Sala-Vila A; Sánchez-Benavides G; González-de-Echávarri JM; Kollmorgen G; Stoops E; Vanmechelen E; Zetterberg H; Blennow K; Molinuevo JL;
    EMBO Mol Med; 2020 Dec; 12(12):e12921. PubMed ID: 33169916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease.
    Santos JRF; Bauer C; Schuchhardt J; Wedekind D; Waniek K; Lachmann I; Wiltfang J; Vogelgsang J
    J Neural Transm (Vienna); 2019 Mar; 126(3):339-348. PubMed ID: 30767082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease.
    Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O
    Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry.
    Gobom J; Brinkmalm A; Brinkmalm G; Blennow K; Zetterberg H
    Mol Cell Proteomics; 2024 Feb; 23(2):100721. PubMed ID: 38246483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice.
    Yukawa K; Yamamoto-Mcguire S; Cafaro L; Hong C; Kamme F; Ikezu T; Ikezu S
    Acta Neuropathol Commun; 2023 Oct; 11(1):166. PubMed ID: 37853497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease.
    Papaliagkas V; Kalinderi K; Vareltzis P; Moraitou D; Papamitsou T; Chatzidimitriou M
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Regulatory Functions of Macrophages and Microglia in Central Nervous System Diseases.
    Poppell M; Hammel G; Ren Y
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum.
    Gobom J; Benedet AL; Mattsson-Carlgren N; Montoliu-Gaya L; Schultz N; Ashton NJ; Janelidze S; Servaes S; Sauer M; Pascoal TA; Karikari TK; Lantero-Rodriguez J; Brinkmalm G; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Mol Neurodegener; 2022 Dec; 17(1):81. PubMed ID: 36510321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Microtubule-Associated Protein Tau in Chemotherapy-Resistant Models of High-Grade Serous Ovarian Carcinoma.
    Barbolina MV
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is liquid biopsy mature enough for the diagnosis of Alzheimer's disease?
    Gong X; Zhang H; Liu X; Liu Y; Liu J; Fapohunda FO; Lü P; Wang K; Tang M
    Front Aging Neurosci; 2022; 14():977999. PubMed ID: 35992602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain.
    Moloney CM; Labuzan SA; Crook JE; Siddiqui H; Castanedes-Casey M; Lachner C; Petersen RC; Duara R; Graff-Radford NR; Dickson DW; Mielke MM; Murray ME
    Alzheimers Dement; 2023 Mar; 19(3):1029-1040. PubMed ID: 35920592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint.
    Alawode DOT; Fox NC; Zetterberg H; Heslegrave AJ
    Front Neurosci; 2022; 16():837390. PubMed ID: 35573283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescent Aptasensor and Colorimetric Aptablot for p-tau231 Detection: Toward Early Diagnosis of Alzheimer's Disease.
    Phan LMT; Cho S
    Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-tau235: a novel biomarker for staging preclinical Alzheimer's disease.
    Lantero-Rodriguez J; Snellman A; Benedet AL; Milà-Alomà M; Camporesi E; Montoliu-Gaya L; Ashton NJ; Vrillon A; Karikari TK; Gispert JD; Salvadó G; Shekari M; Toomey CE; Lashley TL; Zetterberg H; Suárez-Calvet M; Brinkmalm G; Rosa Neto P; Blennow K
    EMBO Mol Med; 2021 Dec; 13(12):e15098. PubMed ID: 34725927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies.
    Yuan A; Nixon RA
    Front Neurosci; 2021; 15():689938. PubMed ID: 34646114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.